Skip to main content
. 2021 Sep 6:1–8. doi: 10.1017/ice.2021.391

Table 3.

Adjusted Odds Ratios (95% CI) for Secondary Bacterial Infections in (3a) COVID-19 versus controls and in (3b) COVID-19 Versus Influenza

Table 3a. COVID-19 Versus Controls

Independent Variable IVAC, aOR (95% CI) PVAP,aOR (95% CI) BSI,aOR (95% CI) Enterococcus BSI,aOR (95% CI) CAUTI,aOR (95% CI)a
COVID-19 4.73 (1.70–13.86)b 10.40 (2.08–52.09) 1.01 (0.56–1.81) 3.75 (1.49–9.41) 0.85 (0.18–3.94)
Age, per year 1.00 (0.98–1.02) 1.00 (0.96–1.05) 1.02 (1.01–1.03) 1.01 (0.99–1.03) 1.01 (0.99–1.03)
Sex, male 1.10 (0.51–2.36) 1.23 (0.27–5.62) 1.33 (1.07–1.67) 1.01 (0.56–1.81) 0.28 (0.14–0.59)
Race or ethnicity
  Black 1.50 (0.45–4.97) 2.25 (0.20–24.88) 0.96 (0.65–1.43) 1.44 (0.57–3.59) 1.57 (0.52–4.71)
  Asian 1.53 (0.62–3.79) 1.81 (0.28–11.61) 0.86 (0.65–1.14) 0.73 (0.31–1.73) 1.31 (0.57–2.98)
  Hispanic/Latino 0.66 (0.23–1.92) 1.30 (0.21–8.29) 0.87 (0.63–1.21) 1.23 (0.58–2.60) 1.52 (0.66–3.47)
Baseline IC 0.54 (0.23–1.92) 0.14 (0.01–1.42) 0.92 (0.73–1.17) 1.30 (0.71–2.41) 1.90 (0.98–3.69)
IS meds 1.27 (0.57–2.81) 1.36 (0.31–5.99) 0.65 (0.50–0.83) 0.65 (0.34–1.22) 3.45 (1.53–7.79)
ALC<500 1.26 (0.52–3.02) 1.97 (0.41–9.53) 2.01 (1.56–2.58) 1.61 (0.81–3.18) 0.90 (0.41–1.99)
LOS, per day 1.00 (0.98–1.04) 1.01 (0.95–1.07) 0.99 (0.97–1.00) 1.01 (0.99–1.03) 1.03 (1.01–1.04)
Central-line days, per day 0.98 (0.95–1.00) 0.98 (0.94–1.03) 0.97 (0.95–0.98) 0.95 (0.93–0.97) 0.97 (0.95–0.99)
Ventilator days, per day 1.09 (1.05–1.13) 1.04 (0.97–1.12) 0.91 (0.88–0.93) 0.98 (0.94–1.02) 1.01 (0.97–1.06)
No. of blood cultures 1.04 (0.96–1.12) 1.03 (0.87–1.22) 1.58 (1.51–1.66) 1.27 (1.18–1.37) 1.06 (0.98–1.16)
Antibiotic days, per day 1.03 (1.01–1.04) 1.01 (0.98–1.05) 1.02 (1.01–1.03) 1.02 (1.00–1.03) 1.00 (0.98–1.03)
SOFA 1.19 (1.08–1.32) 1.33 (1.11–1.60) 1.07 (1.03–1.11) 1.09 (1.00–1.20) 1.00 (0.90–1.11)

Note. CI, confidence interval; IVAC, infection-related ventilator-associated complications; PVAP, probable ventilator-associated pneumonia; BSI, bloodstream infection; CAUTI, catheter-associated urinary tract infection; IC, immunocompromised; IS meds, immunosuppressive medications; ALC<500, absolute lymphocyte count <500 cells/μL at least once during encounter; LOS, length of stay; SOFA, Sequential Organ Failure Assessment score.

a

Urinary catheter days were included as a covariate for the CAUTI outcome only; aOR, 1.06 (1.03–1.09).

b

Covariates significant in the model are in bold.